Sam Slutsky, an analyst from LifeSci Capital, has initiated a new Buy rating on Spyre Therapeutics (SYRE). Sam Slutsky has given his Buy rating due to a combination of factors surrounding Spyre ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback